Better Recovery-Story Buy: Emergent BioSolutions or Invitae?
Sometimes, a company hits a stumbling block -- or several of them. The stock plummets, and investors lose faith. But, in some cases, these down-on-their luck companies are able to turn things around. And if you spot signs of a bright future early enough, you can get in on the stock at a bargain price -- and reap the rewards later.
Two possibilities today are Emergent BioSolutions (NYSE: EBS) and Invitae (NYSE: NVTA). Their share prices have dropped 68% and 54%, respectively, over the past year. Both companies have catalysts ahead that could help lift the shares. But which is the better recovery-story buy? Let's find out.
Emergent BioSolutions specializes in products that address public-health threats. Among these are vaccines for smallpox and anthrax. The company also won contracts to produce coronavirus vaccines for Johnson Johnson and . Unfortunately, back in 2021, manufacturing errors led to a halt in production, and almost 400 million vaccine doses had to be destroyed, according to a Congressional investigation.
Source Fool.com
